Skip to Content

Rimantadine Dosage

Applies to the following strength(s): 100 mg ; 50 mg/5 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Influenza A

Normally recommended dose: 100 mg orally twice a day for 7 days

Usual Adult Dose for Influenza Prophylaxis

Normally recommended dose: 100 mg orally twice a day

Usual Geriatric Dose for Influenza Prophylaxis

Elderly nursing home patients and patients over the age of 65 years: A dose reduction to 100 mg orally once a day is normally recommended.

Usual Geriatric Dose for Influenza A

Elderly nursing home patients and patients over the age of 65 years: A dose reduction to 100 mg orally once a day is normally recommended.

Usual Pediatric Dose for Influenza A

Normally recommended dose:
17 years or older: 100 mg orally twice a day for 7 days

Usual Pediatric Dose for Influenza Prophylaxis

Normally recommended dose:
1 to 9 years: 5 mg/kg (up to 150 mg) orally once a day
10 years or older: 100 mg orally twice a day

Renal Dose Adjustments

Severe renal dysfunction (CrCl 5 to 29 mL/min) or renal failure (CrCl 10 mL/min or less): A dose reduction to 100 mg orally once a day is normally recommended.

Liver Dose Adjustments

Severe liver dysfunction: A dose reduction to 100 mg orally once a day is normally recommended.

Dose Adjustments

Some clinicians recommend 200 mg orally once a day for treatment or prevention of seasonal influenza A virus infection in adults.

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Severe renal dysfunction (CrCl 5 to 29 mL/min) or renal failure (CrCl 10 mL/min or less): A dose reduction to 100 mg orally once a day is normally recommended.

Comments:
-Rimantadine is not removed by hemodialysis.

Other Comments

On the basis of available antiviral testing results, the Centers for Disease Control and Prevention (CDC) recommend that rimantadine not be used for treatment or prophylaxis of currently circulating influenza A virus strains; oseltamivir or zanamivir recommended if antiviral medication needed.

Administration advice:
-Therapy should begin within 48 hours of onset of signs/symptoms of influenza A infection; efficacy of rimantadine started after 48 hours not known. Therapy should be continued for about 7 days from initial onset of symptoms.
-Prophylaxis is generally started when an outbreak of influenza A is documented and continued until it is over, if necessary, or until an immune response is provided by immunization (2 to 4 weeks after vaccination).
-Compounded rimantadine oral suspension preferred for patients who have difficulty swallowing tablets.

Reconstitution/preparation techniques:
-During emergency situations only: For patients who have difficulty swallowing tablets or where lower doses are needed, an oral suspension (10 mg/mL) may be prepared from rimantadine 100 mg tablets using Ora-Sweet(R); the manufacturer's product information should be consulted for compounding procedures.

General:
-Annual vaccination is preferred method for prophylaxis against influenza A; rimantadine should not be considered a substitute.
-To minimize the entrapment of air, the compounded oral suspension should be shaken gently before each use.
-Any remaining suspension must be discarded after completion of therapy or after the labeled expiration date. The compounded oral suspension is stable for 14 days at room temperature; therefore, the maximum amount to be dispensed should not exceed a 14 day supply.

Monitoring:
-General: For side effects in patients with liver or renal dysfunction

Hide